Investigation of biomarkers for predicting effectiveness of treatments for inflammatory bowel diseases

Investigation of biomarkers for predicting effectiveness of treatments for inflammatory bowel diseases - Investigation of biomarkers for predicting effectiveness of treatments for inflammatory bowel diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005032

Enrollment

200

Registered

2011-03-01

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel diseases

Interventions

to measure several inflammatory substances before and after the leukocyteapheresis, anti-TNF alpha antibody and tacrolimus for patients with inflammatory bowel diseases

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are applicable for the treatments of leukocyteapheresis, anti-TNF alpha antibody and tacrolimus Patients who argee informed consent

Exclusion criteria

Exclusion criteria: Patients who are not applicable for the treatments of leukocyteapheresis, anti-TNF alpha antibody and tacrolimus Patients who disargee informed consent

Design outcomes

Primary

Measure	Time frame
To investigate the several inflammatory substances to find out the usefullness biomarkers to predict the efficacy and prognosis of treatments in inflammatory bowel diseases	—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama medical Center, Saitama medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026